Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Taking it up a notch

    Local sensitivity Product R&D Taking it up a notch In a study in Cell, a University of California San Francisco team showed how its synthetic Notch (synNotch) technology turns T cells into "smart" agents that …

    Published on 10/6/2016
  • Table: BioCentury Product Profile

    Local sensitivity Product R&D BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Synthetic Notch (synNotch) receptor circuits for T cell therapies Throttle Switch for chimeric …

    Published on 10/6/2016
  • Safety Factor

    How Pfizer aims to compete in the Factor XIa space

    Pfizer and UCSF researchers believe their anti-Factor XIa mAb can serve some subpopulations left behind by the safety gaps of Factor Xa inhibitors.

    Published on 9/29/2016
  • Figure: Counting factors

    Safety Factor Product R&D Counting factors In a Science Translational Medicine study, Pfizer Inc. (NYSE:PFE) and University of California San Francisco researchers showed the anti-clotting effects of their anti-…

    Published on 9/29/2016
  • Table: BioCentury Product Profile

    Safety Factor Product R&D BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Factor XIa-blocking mAb, plus antidote reversal agent for safety Concept Blocking Factor XIa to prevent …

    Published on 9/29/2016
  • In the CRISPR tea leaves

    How deal flow is beginning to reveal CRISPR company strategies

    The deal flow by foundational CRISPR companies is providing clues into what they are prioritizing to take into the clinic.

    Published on 9/22/2016
  • Figure: 2 patents, 3 inventors, 4 companies

    In the CRISPR tea leaves Strategy 2 patents, 3 inventors, 4 companies The foundational CRISPR patents have undergone a series of licensing transactions, resulting in four therapeutically focused companies with …

    Published on 9/22/2016
  • Table: CRISPR collaborations

    In the CRISPR tea leaves Strategy CRISPR collaborations Select licensing and collaboration deals made by the four foundational CRISPR companies. Since December 2014, at least 17 partnerships or licensing deals were…

    Published on 9/22/2016
  • Table: γδ Companies

    Enter GammaDelta Product R&D γδ Companies Select companies developing γδ T cell-based cell therapies for cancer. Source: BCIQ: BioCentury Online Intelligence; company websites Company Product(s) Description T …

    Published on 9/15/2016
  • Table: BioCentury Product Profile

    Enter GammaDelta Product R&D BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product γδ T cell therapy Concept Cell therapy for cancer using patient- or donor-sourced tissue-resident γδ …

    Published on 9/15/2016
  • Enter GammaDelta

    How GammaDelta's T cells could become the newest cancer immunotherapy class

    Abingworth launched GammaDelta Therapeutics today to develop a new type of T cell therapy for cancer.

    Published on 9/15/2016
  • Box: Bad guy's good side

    Biased against pain Targets & Mechanisms Bad guy's good side While the β-arrestin ARRB2 has been viewed as the bad actor in the side effects of opioid drugs, a Duke University Medical Center team has discovered the…

    Published on 9/1/2016
  • Figure: Breaking form

    Biased against pain Targets & Mechanisms Breaking form Creating safer opioid analgesics may require breaking away from the standard morphinan scaffold (red) found in classical opioids such as morphine, which bind …

    Published on 9/1/2016
  • Table: BioCentury Product Profile

    Biased against pain Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product Biased agonist at the mu opioid receptor, MOR (PZM21 or derivative) Concept MOR binding …

    Published on 9/1/2016
  • Biased against pain

    How Epiodyne aims to make opioids safer

    Pushing the limits of computational drug discovery, an academic team finds a new type of molecule that separates good from bad signaling at opioid receptors.

    Published on 9/1/2016
  • Figure: Cleanup crew

    Forty Seven and counting Targets & Mechanisms Cleanup crew In a pair of Nature and Science Translational Medicine studies, Stanford University teams have shown blocking the "don't eat me" cell surface protein CD47 …

    Published on 8/25/2016
  • Table: BioCentury Product Profile

    Forty Seven and counting Targets & Mechanisms BioCentury Product Profile BioCentury Product Profile INNOVATION STAGE Product CD47-blocking mAb CD47-blocking mAb or fusion protein Concept Blocking CD47 can …

    Published on 8/25/2016
  • Table: BioCentury Product Profile

    Forty Seven and counting Targets & Mechanisms BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product CD47-blocking mAb CD47-blocking mAb or fusion protein Concept Blocking CD47 can …

    Published on 8/25/2016
  • Table: Chasing CD47

    Forty Seven and counting Targets & Mechanisms Chasing CD47 At least six companies are developing compounds to block the anti-phagocytic cell surface protein CD47, either with CD47-targeting antibodies or with …

    Published on 8/25/2016
  • Forty Seven and counting

    Stanford and Forty Seven Inc. count up new indications for CD47 blockade

    With CD47 gaining status as the go-to target in oncology, a pair of Stanford studies suggest the target could extend to cardiovascular disease, transplant biology and more.

    Published on 8/25/2016
  • Go small or go home

    A portable manufacturing unit for single doses of biologics

    An MIT duo has coupled a small scale bioreactor with cellular engineering to produce single-dose biologics, with applications ranging from process development to the battlefield.

    Published on 8/18/2016
  • Figure: Just a little culture

    Go small or go home Tools & Techniques Just a little culture Massachusetts Institute of Technology (MIT) scientists have coupled a state-of-the-art microbioreactor and a genetically engineered yeast strain to …

    Published on 8/18/2016
  • Table: BioCentury Product Profile

    Go small or go home Tools & Techniques BioCentury Product Profile BIOCENTURY PRODUCT PROFILE INNOVATION STAGE Product Cell line optimized for continuous, switchable production of multiple proteins Concept …

    Published on 8/18/2016
  • SHP-2 sets sail

    How NIBR made the first drug-like SHP-2 inhibitor

    After an industry-wide effort of nearly 20 years, an NIBR team may have cracked the problem of how to drug protein tyrosine phosphatases.

    Published on 8/11/2016
  • Figure: Equilibrating SHP-2

    SHP-2 sets sail Product R&D Equilibrating SHP-2 Researchers at Novartis AG's Novartis Institutes for BioMedical Research (NIBR) have shown that the protein tyrosine phosphatase SHP-2 - a promising cancer target - …

    Published on 8/11/2016

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993